February 14, 2025
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer compared with treatment […]
February 14, 2025
Among more than 3000 men from low-income communities who were screened for various health issues at mobile clinics, one had stage IV and none had metastatic […]
February 13, 2025
TOPLINE: Among breast cancer survivors who became pregnant, 34% resumed endocrine therapy (ET) by 2 years postdelivery, with a 19% cumulative incidence of subsequent breast cancer […]
February 13, 2025
TOPLINE: Cabozantinib improves progression-free survival (PFS) in patients with advanced extrapancreatic neuroendocrine tumors and pancreatic neuroendocrine tumors compared with placebo. METHODOLOGY: Cabozantinib, an oral small-molecule inhibitor […]
February 13, 2025
When Erin Reardon, MD, started the doxorubicin phase of her neoadjuvant chemotherapy, she was already convinced she had crossed the threshold into overtreatment for her stage […]
February 12, 2025
The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for brentuximab vedotin (Adcetris; Seagen, Inc., a Pfizer subsidiary), in combination with […]
February 12, 2025
Contrary to misconceptions among medical professionals and patients alike, individuals born with sickle cell trait (SCT) show no risk of experiencing the acute pain crises known […]
February 12, 2025
Suchitra Sundaram, MD Despite her specialized focus on treating lymphoid malignancies, Suchitra Sundaram, MD, said that she feels most driven by the diversity of her experiences […]
February 12, 2025
The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically, […]